Xipere is owned by Bausch And Lomb Inc.
Xipere contains Triamcinolone Acetonide.
Xipere has a total of 3 drug patents out of which 0 drug patents have expired.
Xipere was authorised for market use on 22 October, 2021.
Xipere is available in suspension;injection dosage forms.
Xipere can be used as treatment of macular edema associated with uveitis.
The generics of Xipere are possible to be released after 02 May, 2034.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US8636713||BAUSCH AND LOMB INC||Methods and devices for drug delivery to ocular tissue using microneedle|| |
(4 years from now)
|US9636332||BAUSCH AND LOMB INC||Methods and devices for the treatment of ocular diseases in human subjects|| |
(10 years from now)
|US9937075||BAUSCH AND LOMB INC||Apparatus and methods for ocular injection|| |
(11 years from now)
|New Product (NP)||Oct 22, 2024|
Market Authorisation Date: 22 October, 2021
Treatment: Treatment of macular edema associated with uveitis
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic